First Tracks Biotherapeutics (NASDAQ:TRAX) Now Covered by Analysts at Barclays

Barclays initiated coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $40.00 price objective on the stock.

Separately, UBS Group began coverage on shares of First Tracks Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $42.50.

First Tracks Biotherapeutics Stock Up 11.0%

Shares of TRAX stock opened at $18.87 on Wednesday. First Tracks Biotherapeutics has a 1 year low of $14.79 and a 1 year high of $26.80.